Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma

Chao Gu; Katherine Upchurch; James Mamaril-Davis; Matthew Wiest; Bobby Lanier; Mark Millard; Jacob Turner; Hye Mee Joo; Sang Kon Oh

doi:10.1111/cea.13696

Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma

Chao Gu, Katherine Upchurch, James Mamaril-Davis, Matthew Wiest, Bobby Lanier, Mark Millard, Jacob Turner, Hye Mee Joo, Sang Kon Oh

Mathematics and Statistics

Producción científica: Letter › revisión exhaustiva

Idioma original	English
Páginas (desde-hasta)	1196-1199
Número de páginas	4
Publicación	Clinical and Experimental Allergy
Volumen	50
N.º	10
DOI	https://doi.org/10.1111/cea.13696
Estado	Published - oct 1 2020

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology

Acceder al documento

10.1111/cea.13696

Otros archivos y enlaces

Citar esto

@article{4a82e8f113f2478aa597df44988d5ad5,

title = "Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma",

keywords = "asthma, biomarkers, body mass index, immunoglobulin E, obesity, omalizumab",

author = "Chao Gu and Katherine Upchurch and James Mamaril-Davis and Matthew Wiest and Bobby Lanier and Mark Millard and Jacob Turner and Joo, {Hye Mee} and Oh, {Sang Kon}",

note = "Funding Information: This study was supported by the American Asthma Foundation (AAF15‐0038, S.O) and an Investigator‐Initiated Study Grant from Genentech (ML28019, SO). ",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/cea.13696",

language = "English",

volume = "50",

pages = "1196--1199",

number = "10",

}

TY - JOUR

T1 - Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma

AU - Gu, Chao

AU - Upchurch, Katherine

AU - Mamaril-Davis, James

AU - Wiest, Matthew

AU - Lanier, Bobby

AU - Millard, Mark

AU - Turner, Jacob

AU - Joo, Hye Mee

AU - Oh, Sang Kon

N1 - Funding Information: This study was supported by the American Asthma Foundation (AAF15‐0038, S.O) and an Investigator‐Initiated Study Grant from Genentech (ML28019, SO).

PY - 2020/10/1

Y1 - 2020/10/1

KW - asthma

KW - biomarkers

KW - body mass index

KW - immunoglobulin E

KW - obesity

KW - omalizumab

UR - http://www.scopus.com/inward/record.url?scp=85087757148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087757148&partnerID=8YFLogxK

U2 - 10.1111/cea.13696

DO - 10.1111/cea.13696

M3 - Letter

C2 - 32585057

AN - SCOPUS:85087757148

SN - 0954-7894

VL - 50

SP - 1196

EP - 1199

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

IS - 10

ER -